Show simple item record

dc.creatorNoy-Porat, Tal
dc.creatorMakdasi, Efi
dc.creatorAlcalay, Ron
dc.creatorMechaly, Adva
dc.creatorLevy, Yinon
dc.creatorBercovich-Kinori, Adi
dc.creatorZauberman, Ayelet
dc.creatorTamir, Hadas
dc.creatorYahalom-Ronen, Yfat
dc.creatorIsraeli, Ma’ayan
dc.creatorEpstein, Eyal
dc.creatorAchdout, Hagit
dc.creatorMelamed, Sharon
dc.creatorChitlaru, Theodor
dc.creatorWeiss, Shay
dc.creatorPeretz, Eldar
dc.creatorRosen, Osnat
dc.creatorParan, Nir
dc.creatorYitzhaki, Shmuel
dc.creatorShapira, Shmuel C.
dc.creatorIsraely, Tomer
dc.creatorMazor, Ohad
dc.creatorRosenfeld, Ronit
dc.date.accessioned2020-09-18T03:20:00Z
dc.date.available2020-09-18T03:20:00Z
dc.date.created2020-08-27
dc.identifier.issn2041-1723spa
dc.identifier.otherhttps://www.nature.com/articles/s41467-020-18159-4#article-infospa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/13440
dc.format.extent7 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherNature Communicationsspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectSARS-CoV-2spa
dc.titleA panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopesspa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.rights.localAbierto (Texto Completo)spa
dc.identifier.doihttps://doi.org/10.1038/s41467-020-18159-4spa
dc.description.abstractenglishThe novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD. A subset of the antibodies exert their inhibitory activity by abrogating binding of the RBD to the human ACE2 receptor. The human monoclonal antibodies described here represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.spa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record